Milne, George W. A. (2005). Gardner's commercially important chemicals: synonyms, trade names, and properties. New York: Wiley-Interscience. pp. 325. ISBN978-0-471-73518-2
“Editorial: Unproven methods of cancer management: hydrazine sulfate”, CA Cancer J Clin26 (2): 108–10, (1976), doi:10.3322/canjclin.26.2.108, PMID816429
“Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer”, J. Clin. Oncol.8 (1): 9–15, (January 1990), doi:10.1200/jco.1990.8.1.9, PMID1688616
“Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer”, J. Clin. Oncol.12 (6): 1126–9, (June 1994), doi:10.1200/JCO.1994.12.6.1126, PMID8201374
“Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B”, J. Clin. Oncol.12 (6): 1113–20, (June 1994), doi:10.1200/JCO.1994.12.6.1113, PMID8201372
“Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer”, J. Clin. Oncol.12 (6): 1121–5, (June 1994), doi:10.1200/JCO.1994.12.6.1121, PMID8201373
“Systematic review of the treatment of cancer-associated anorexia and weight loss”, J. Clin. Oncol.23 (33): 8500–11, (November 2005), doi:10.1200/JCO.2005.01.8010, PMID16293879
Nagappan, R.; Riddell, T. (2000), “Pyridoxine therapy in a patient with severe hydrazine sulfate toxicity”, Critical Care Medicine28 (6): 2116–18, doi:10.1097/00003246-200006000-00076, PMID10890675.
Gold, J. (1999), “Long term complete response in patient with advanced, localized NSCLC with hydrazine sulfate, radiation and Carboplatin, refractory to combination chemotherapy”, Proceedings of the American Association for Cancer Research (40): 642. Abstract.Archived 2016-03-03 at the Wayback Machine.
“Editorial: Unproven methods of cancer management: hydrazine sulfate”, CA Cancer J Clin26 (2): 108–10, (1976), doi:10.3322/canjclin.26.2.108, PMID816429
“Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer”, J. Clin. Oncol.8 (1): 9–15, (January 1990), doi:10.1200/jco.1990.8.1.9, PMID1688616
“Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer”, J. Clin. Oncol.12 (6): 1126–9, (June 1994), doi:10.1200/JCO.1994.12.6.1126, PMID8201374
“Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B”, J. Clin. Oncol.12 (6): 1113–20, (June 1994), doi:10.1200/JCO.1994.12.6.1113, PMID8201372
“Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer”, J. Clin. Oncol.12 (6): 1121–5, (June 1994), doi:10.1200/JCO.1994.12.6.1121, PMID8201373
“Systematic review of the treatment of cancer-associated anorexia and weight loss”, J. Clin. Oncol.23 (33): 8500–11, (November 2005), doi:10.1200/JCO.2005.01.8010, PMID16293879
Nagappan, R.; Riddell, T. (2000), “Pyridoxine therapy in a patient with severe hydrazine sulfate toxicity”, Critical Care Medicine28 (6): 2116–18, doi:10.1097/00003246-200006000-00076, PMID10890675.
Gold, J. (1999), “Long term complete response in patient with advanced, localized NSCLC with hydrazine sulfate, radiation and Carboplatin, refractory to combination chemotherapy”, Proceedings of the American Association for Cancer Research (40): 642. Abstract.Archived 2016-03-03 at the Wayback Machine.